TrialBlood advances2026

A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation.

Jennifer L Crombie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.